VR Adviser LLC Has $61.73 Million Stock Holdings in Pharvaris (NASDAQ:PHVS)

VR Adviser LLC lowered its stake in Pharvaris (NASDAQ:PHVS - Free Report) by 5.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,220,130 shares of the company's stock after selling 175,476 shares during the quarter. Pharvaris accounts for approximately 4.2% of VR Adviser LLC's portfolio, making the stock its 8th largest position. VR Adviser LLC owned approximately 6.16% of Pharvaris worth $61,730,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of PHVS. JPMorgan Chase & Co. grew its position in Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Pharvaris in the 4th quarter valued at $64,000. Barclays PLC acquired a new stake in Pharvaris in the 3rd quarter valued at $106,000. KLP Kapitalforvaltning AS acquired a new stake in Pharvaris in the 4th quarter valued at $111,000. Finally, Point72 Asset Management L.P. acquired a new stake in Pharvaris in the 4th quarter valued at $152,000.

Analysts Set New Price Targets

PHVS has been the subject of several research reports. Cantor Fitzgerald reduced their price target on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. JMP Securities lifted their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Price Performance

PHVS opened at $16.69 on Tuesday. The company has a market capitalization of $872.72 million, a price-to-earnings ratio of -5.96 and a beta of -2.85. The firm's fifty day moving average price is $15.39 and its two-hundred day moving average price is $17.53. Pharvaris has a 1 year low of $11.51 and a 1 year high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). As a group, equities analysts anticipate that Pharvaris will post -2.71 EPS for the current year.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

Want to see what other hedge funds are holding PHVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pharvaris (NASDAQ:PHVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.